$1.63
+0.01 (+0.62%)
Open$1.58
Previous Close$1.62
Day High$1.71
Day Low$1.58
52W High$11.64
52W Low$1.09
Volume—
Avg Volume1.48M
Market Cap38.42M
P/E Ratio—
EPS$-1.69
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+935.0% upside
Current
$1.63
$1.63
Target
$16.87
$16.87
$11.09
$16.87 avg
$25.84
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 54.1K | 105.4K | 11.20M |
| Net Income | -50,192,005 | -88,021,832 | 1.78M |
| Profit Margin | -91,866.0% | -87,272.7% | 15.9% |
| EBITDA | -51,685,348 | -95,676,306 | 2.32M |
| Free Cash Flow | — | — | 977.1K |
| Rev Growth | -48.7% | -48.7% | +3.1% |
| Debt/Equity | — | — | 0.37 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |